Anti-PD-1 monoclonal antibody (609A) recombinant humanized
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-PD-1 monoclonal antibody (609A) recombinant humanized, covering 2021-11-30 to 2021-11-30. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma [Phase 2]